Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.

Anderson, K M

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. [electronic resource] - Journal of the American College of Cardiology Jun 2001 - 2059-65 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0735-1097

10.1016/s0735-1097(01)01290-6 doi


Abciximab
Antibodies, Monoclonal--therapeutic use
Atherectomy, Coronary
Coronary Disease--mortality
Humans
Immunoglobulin Fab Fragments--therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors
Randomized Controlled Trials as Topic
Stents
Survival Analysis